Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics, Inc. reported an insider equity transaction by its Chief Executive Officer, who is also a director. On 12/31/2025, the reporting person exercised a stock option for 30,000 shares of common stock at an exercise price of $2.08 per share and acquired those shares. On the same date, the reporting person sold a total of 30,000 shares of common stock in two transactions: 23,986 shares at a weighted average price of $77.9508 and 6,014 shares at a weighted average price of $78.5187, all pursuant to a Rule 10b5-1 trading plan adopted on September 6, 2024. Following these transactions, the reporting person beneficially owned 663,077 shares of common stock directly and 275,559 derivative securities (stock options), with the option relating to these 30,000 shares fully vested and exercisable.
Kymera Therapeutics, Inc. reported an insider stock option exercise by its Chief Executive Officer and director on 12/17/2025. The CEO exercised a stock option to acquire 2,595 shares of common stock at an exercise price of $38.53 per share. Following this transaction, he beneficially owns 663,077 shares of common stock directly.
The exercised option was a stock option (right to buy) covering 2,595 shares of common stock, with an exercise price of $38.53 and an expiration date of 03/01/2032. After the transaction, 272,505 derivative securities (stock options) remain beneficially owned directly. The filing notes that the shares underlying this stock option are fully vested and exercisable.
Kymera Therapeutics, Inc. director reports option exercises and stock sales. On 12/17/2025, the reporting person, a director of Kymera Therapeutics (KYMR), exercised stock options and sold common shares under a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2025.
The director exercised options for 12,563 shares at $49.10, 12,000 shares at $27.67, and 3,000 shares at $31.20, acquiring a total of 27,563 common shares. On the same date, they sold 14,505 shares at a weighted average price of $81.557, 7,959 shares at $82.3422, 4,099 shares at $83.4507, and 1,000 shares at $84.07, leaving 0 directly owned common shares.
Following these transactions, the director continued to hold stock options, including 7,500 options with a $49.10 exercise price expiring on June 15, 2031, and 13,000 options with a $31.20 exercise price expiring on June 18, 2034. All underlying option shares were reported as fully vested and exercisable.
Kymera Therapeutics, Inc. reported insider activity showing that a director, filing individually, completed multiple sales of Kymera common stock on December 10–12, 2025 through affiliated investment funds. The transactions involved several blocks of common stock sold at weighted average prices including $88.64, $89.25, $90.14, $92.41, $93.20, $91.23 and $91.04 per share, with underlying trade prices ranging from $88.00 to about $93.69 per share as described in the footnotes.
After these sales, Atlas Venture Fund X, L.P. held 3,974,481 Kymera shares and Atlas Venture Opportunity Fund I, L.P. held 685,393 shares, reported as indirectly beneficially owned by the director through general partner entities. The director disclaims beneficial ownership of these fund-held securities except to the extent of any pecuniary interest.
Kymera Therapeutics, Inc. reported insider purchases by affiliated Baker Brothers funds in a public stock offering that closed on December 11, 2025. Investment fund 667, L.P. bought 167,192 shares of Kymera common stock, and Baker Brothers Life Sciences, L.P. bought 1,838,621 shares, each at a price to the public of $86.00 per share in an underwritten offering.
After these transactions, 667 is listed as beneficially owning 701,326 Kymera shares and Life Sciences 7,955,916 shares, held indirectly through their partnership structures. The reporting group includes Baker Bros. Advisors LP, its general partner, and Julian C. Baker and Felix J. Baker, who describe advisory and partnership arrangements and disclaim beneficial ownership beyond their pecuniary interest. Felix J. Baker serves on Kymera’s board, and the other reporting persons are treated as directors by deputization due to this board representation.
Kymera Therapeutics, Inc. reported insider activity by its Chief Medical Officer, who filed a Form 4 for transactions in the company’s common stock on 12/08/2025.
The filing shows the officer exercised a stock option for 49,307 shares of common stock at an exercise price of $5.33 per share and, on the same date, sold common stock in multiple transactions with weighted average prices including $87.3711, $88.0215, $89.4264, $90.1226, $91.4639 and $92.19. These trades were effected under a Rule 10b5-1 trading plan dated June 2, 2025. After the transactions, the officer directly beneficially owned 109,992 shares of common stock and 34,083 stock options with a $5.33 exercise price.
Kymera Therapeutics, Inc. reported that it hosted a conference call on December 8, 2025 to discuss results from its BroADen Phase 1b atopic dermatitis patient trial of KT-621, described as a first-in-class, oral STAT6 degrader. The company furnished a related slide presentation as Exhibit 99.1, noting that this material is provided for informational purposes and is not deemed “filed” for liability under Section 18 of the Exchange Act or automatically incorporated into other securities filings. Kymera also stated it undertakes no obligation to update, supplement, or amend the slide materials.
Kymera Therapeutics (KYMR) filed its Q3 2025 10-Q, highlighting a strong liquidity position and ongoing collaboration-driven revenue. Cash, cash equivalents and marketable securities totaled $978.7 million as of September 30, 2025, supported by a June–July follow-on offering with approximately $288.4 million in aggregate gross proceeds. Total assets were $1.10 billion and stockholders’ equity was $946.3 million.
For Q3 2025, the company reported collaboration revenue of $2.764 million, research and development expense of $74.094 million, and a net loss of $82.175 million (basic and diluted net loss per share $0.94). Year-to-date through Q3, collaboration revenue was $36.341 million, net loss was $224.370 million, and cash used in operating activities was $166.144 million. Deferred revenue was $37.236 million, including $37.2 million from the $40.0 million upfront payment in the Gilead molecular glue degrader agreement, to be recognized over an estimated 1.5 years. Under the Sanofi IRAK4 collaboration, the company recognized $33.6 million year-to-date and remains eligible for up to $975 million in future milestones tied to development, regulatory and commercial events. As of October 31, 2025, common shares outstanding were 71,949,027.
Kymera Therapeutics, Inc. filed a current report to note that it announced its financial results for the quarter ended September 30, 2025. The company is furnishing, as an exhibit, a press release that provides details on its results of operations and financial condition for that quarter.
The report clarifies that the press release and related information are being furnished rather than filed under securities laws, which affects how they are treated for certain legal liability and incorporation-by-reference purposes.
Kymera Therapeutics (KYMR) reported insider transactions by its Chief Executive Officer on 10/29/2025 under a Rule 10b5-1 trading plan dated September 6, 2024. The CEO exercised 30,000 stock options at an exercise price of $2.08 per share and acquired 30,000 shares, then sold 30,000 shares in three trades at weighted average prices of $59.7225, $61.0186, and $61.4576.
The filing notes these sales occurred in multiple transactions within disclosed price ranges. Following the transactions, the reporting person held 660,482 shares of common stock directly. The stock option reported was fully vested and exercisable, and 405,559 derivative securities were beneficially owned following the transactions.